[Comment] Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older pa tients with RAS wild-type metastatic colorectal cancer:an analysis of the randomised trial FIRE-3
[Background] The evidence on the efficacy of anticancer therapy is limited in older patients with metastatic colorectal cancer (mCRC). This retrospective analysis of phase III FIRE-3 trial assesses the efficacy of FOLFIRI plus either cetuximab or bevacizumab according to the patients' age and s...
Saved in:
| Main Author: | Wu Deqing |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Editorial Office of Journal of Colorectal & Anal Surgery
2022-08-01
|
| Series: | 结直肠肛门外科 |
| Online Access: | https://jcas.gxmuyfy.cn/cn/wqll/paper.html?id=394&cateName=2022%E5%B9%B4%20%E7%AC%AC28%E5%8D%B7%20%E7%AC%AC4%E6%9C%9F |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
First-line treatment of anti-EGFR monoclonal antibody cetuximab β plus FOLFIRI versus FOLFIRI alone in Chinese patients with RAS/BRAF wild-type metastatic colorectal cancer: a randomized, phase 3 trial
by: Yuankai Shi, et al.
Published: (2025-05-01) -
Bevacizumab versus aflibercept with FOLFIRI after FOLFOX and bevacizumab in RAS mutant metastatic colon cancer a Turkish oncology group study
by: Serhat Sekmek, et al.
Published: (2024-11-01) -
Prolonged Complete Response in a Patient with Metastatic Pancreatic Adenocarcinoma after FOLFIRINOX Chemotherapy and Maintenance with FOLFIRI
by: Christos Nikolaou, et al.
Published: (2015-01-01) -
A Case of Advanced Gastric Cancer with Folfiri as a Preoperative Chemotherapy
by: Hieu Van Nguyen, et al.
Published: (2019-01-01) -
[Comment] Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): a randomized controlled trial
by: Zhang Rongxin
Published: (2024-08-01)